| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_883ef14066c153ff611ef557b6c22f71 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07B2200-07 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D495-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4365
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D495-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P7-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4365 |
| filingDate |
2011-01-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f530f4c15f2363e8af030fdc331e8ffe
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2da3e3d348204c8f96c9f943618d4eda
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d8c707657f921401fab36add0c7db194
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4510e480b6ef7453d2a8451a59dd1989 |
| publicationDate |
2012-12-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-2532668-A1 |
| titleOfInvention |
Optically active 2-hydroxy tetrahydrothienopyridine derivatives, preparation method and use in manufacture of medicament thereof |
| abstract |
Optically active 2-hydroxytetrahydrothienopyridine derivatives represented by Formula I and pharmaceutically acceptable salts, preparation method and use in the manufacture of a medicament thereof are disclosed. The pharmacodynamic experiment results show that the present compounds of Formula I are useful for inhibiting platelet aggregation. The pharmacokinetic experiment results show that the present compound of Formula I can be converted in vivo into pharmacologically active metabolites and are therefore useful for inhibiting platelet aggregation. Therefore, the present compounds are useful for the manufacture of a medicament for preventing or treating thrombosis and embolism related diseases. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2698371-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2698371-A4
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2613783-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2012025942-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-3048108-A4
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-3048108-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-3674306-A4
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2613783-A1 |
| priorityDate |
2010-02-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |